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Diabetes mellitus (DM) is a common medical condition in both the 
developed and developing worlds, affecting >420 million people 
worldwide.[1] It is projected that type 2 DM (DM2) will have a 
global prevalence of 7.7% (439 million people) by the year 2030.[2] 
Major depressive disorder (MDD) too is a disorder affecting a large 
proportion of the population. A national epidemiological survey 
by Hasin et al.[3] showed that MDD represents a heavy burden of 
disease, with a lifetime prevalence of 13.2% in a North American 
population. The lifetime prevalence of MDD in South Africa (SA) 
is said to be 9.7%.[4]
Numerous studies conducted in the past decade show a definite 
association between DM2 and MDD, the former increasing the risk 
of the latter and vice versa.[5-9] In 2010, a systematic review showed 
that patients with DM2 have a 24% increased risk of developing 
MDD compared with those without DM2.[10] According to a study 
analysing individuals from 47 countries published in 2013, DM2 
is associated with a two-fold increase in risk of developing MDD 
worldwide – except in Africa.[11] Mommersteeg et al.[11] noted that 
their study had several limitations and cited underdiagnosis, cultural 
differences and variability of the reliability of self-reported depressive 
symptoms as potential reasons for their findings. Their conclusion 
was challenged by a group of researchers in Zambia, who showed 
that major depressive symptoms were common in the Zambian 
population with DM2.[12] Although research concerning individuals 
with type 1 DM (DM1) has focused mainly on young patients, an 
increased prevalence of MDD was also found in these individuals. [13] 
It is well known that DM increases cardiovascular disease risk, as an 
independent variable and as part of a group of disorders. Patients 
who have both DM2 and MDD have a combined two- to three-fold 
increased risk of cardiovascular disease, especially strokes.[14] Van 
der Feltz-Cornelius et al.[15] concluded that good glycaemic control 
requires attention to be directed towards both DM and MDD.
It can be extrapolated from the above that comorbid MDD in 
individuals with DM poses a significant public health issue. Shrestha 
et al.[16] published data highlighting its economic impact, with 
substantial increases in health expenditure documented, while Hay 
et al.[17] showed the cost benefits of a collaborative management 
approach in patients with both DM and MDD. Data on the prevalence 
and effect of MDD in South Africans appear to be limited.
Objectives
To sensitise clinicians to and shed light on the potentially life-
threatening combination of DM and MDD by determining: (i) the 
prevalence of MDD; and (ii) the effect of MDD on glycaemic control 
in a group of patients attending a specialised diabetes clinic in 
Pietermaritzburg, SA.
Methods
This article forms part of research for the purposes of a thesis. In 
an observational, cross-sectional study, voluntary adult participants 
who attended a specialised diabetes clinic at Edendale Hospital, a 
900-bed public sector, urban regional hospital in Pietermaritzburg, 
were consecutively sampled over a period of 3 months (1 March - 31 
May 2017). All consenting adult patients with DM1 and DM2 were 
considered for inclusion in the study. Adolescents were excluded. 
The sample size required at a type 1 error of 5% was 135, assuming 
the hypothesis is correct that the prevalence of major depressive 
symptoms is not higher in patients in Africa.[11]
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Objectives. To determine the prevalence of MDD in a cohort of patients with DM and its effect on glycaemic control.
Methods. A cross-sectional study was performed at a diabetes clinic at Edendale Hospital, Pietermaritzburg, South Africa (1 March - 
31 May 2017). A total of 176 participants were enrolled. Participants completed the Patient Health Questionnaire-9 (PHQ-9), with a score 
of ≥10 representing a diagnosis of MDD. Higher PHQ-9 scores translate into more severe MDD. A surrogate for glycaemic control, glycated 
haemoglobin (HbA1c) blood testing, was also performed.
Results. The majority of participants were female and suffered from DM2. The mean age was 54.4 years. The prevalence of MDD in the 
study population was 46.6%. A significantly positive linear relationship was shown between PHQ-9 score and HbA1c (p=0.018253).
Conclusions. MDD appears to constitute a large burden of disease in our population of individuals with DM. A relationship between the 
severity of the MDD and HbA1c suggests that prompt intervention in both conditions is likely to improve health outcomes.
S Afr Med J 2019;109(1):58-61. DOI:10.7196/SAMJ.2019.v109i1.13356
59       January 2019, Vol. 109, No. 1
RESEARCH
Each participant was allocated a number, 
and their age, sex, diabetes type, Patient 
Health Questionnaire-9 (PHQ-9) score and 
laboratory reference number for the glycated 
haemoglobin (HbA1c) test were recorded 
for analysis on a standardised clinical sheet. 
In addition, certain potential confounders 
were recorded for analysis: hypothyroidism, 
epilepsy, HIV and body mass index (BMI).
Participants were presented with the 
PHQ-9 in either English or isiZulu. The 
PHQ-9 is a well-developed, reliable screening 
tool for MDD, with a score of ≥10 having 
a sensitivity of 88% and a specificity of 
88% for the diagnosis of MDD, with higher 
scores translating into increasing severity of 
MDD. [18] The PHQ-9 was validated by Bhana 
et al.[19] in 2015 for use in SA on chronic care 
patients. They used a score of ≥9 to diagnose 
MDD. When compared with the Patient 
Health Questionnaire-2 and the Structured 
Clinical Interview for DSM-IV, the sensitivity 
and specificity of the PHQ-9 were 49% and 
94%, respectively. Despite its considerably 
lower sensitivity, Bhana et al.[19] determined 
that the PHQ-9 can be a valuable tool for 
identifying comorbid depression. The PHQ-9 
was validated in isiZulu for the purposes of 
our study.
HbA1c (mmol/mol) blood results from 
samples obtained on the day of consultation 
were recorded (for conversion into HbA1c 
percentage, see Table 1). HbA1c is a reference 
system developed by the International 
Federation of Clinical Chemistry to 
standardise HbA1c reporting worldwide. 
The local National Health Laboratory Service 
used the Bio-Rad D10 machine (Bio-Rad, 
South Africa) to determine HbA1c values.
The protocol and all tools needed for 
this study were presented for assessment to 
the Biomedical Research Ethics Committee 
of the University of KwaZulu-Natal. Full 
approval was obtained (ref. no. BE483/16).
Statistical analyses were performed to 
determine the prevalence of MDD and 




Data for a total of 176 participants were 
analysed. Their mean age was 54.4 (standard 
deviation (SD) 14.8) years (range 19 - 96); 
125 (71.0%) were female and 51 (29.0%) 
male; and 20 (11.4%) had DM1 and 151 
(85.8%) had DM2 (DM type was not 
recorded for the remaining 5 participants). 
The mean PHQ-9 score was 9.26 (SD 5.67).
No relationship was found between age 
and PHQ-9 score (p=0.90), and no difference 
in PHQ-9 score was evident between female 
and male participants (p=0.44).
Prevalence of MDD in participants 
with DM
A total of 82 participants scored ≥10 on the 
PHQ-9 and were diagnosed with MDD. The 
prevalence of MDD in patients with DM was 
therefore 46.6%.
HbA1c and MDD in DM
The mean HbA1c value was 76.89 (SD 25.26) 
mmol/mol.
A positive, statistically significant relation-
ship was shown between the PHQ-9 score 
and HbA1c (p=0.018253) (Fig. 1).
No statistically significant difference in 
HbA1c was found between participants 
diagnosed with MDD (mean 80.0; 95% 
confidence interval (CI) 74.0 - 86.0) and 
those not diagnosed with MDD (mean 74.1; 
95% CI 69.5 - 78.7) (p=0.1226).
Analysis of potential confounders
A total of 170 participants had all the 
variables required for statistical analysis of 
the potential confounders recorded.
A total of 6 participants were known to 
have hypothyroid disease. Compared with 
participants without hypothyroidism, no 
statistical difference in PHQ-9 score was 
evident between the two groups (p=0.65).
A total of 12 participants were known to 
have epilepsy. Compared with participants 
without comorbid epilepsy, no statistical 
difference in PHQ-9 score was evident 
between the two groups (p=0.82).
A total of 35 participants were known to 
be HIV-positive. Compared with partici-
pants who were HIV-negative, no statistical 
difference in PHQ-9 score was evident 
between the two groups (p=0.54).
There was no statistically significant 
relationship between BMI and PHQ-9 score 
(p=0.69). 
Discussion
Our study population consisted of patients 
attending a specialised diabetes clinic in a 
900-bed public sector, urban regional hospital 
in Pietermaritzburg, SA. The majority of 
participants were female, which concurs with 
the finding of a study performed at the same 
clinic in 2015 that >77% of clinic attendees 
were female.[20] There was no difference in 
PHQ-9 score between our female and male 
participants (p=0.44).
The mean age of participants was 54.4 
years, and no relationship was evident 
between age and PHQ-9 score (p=0.90). 
According to the Society for Endocrinology, 
Metabolism and Diabetes of South Africa’s 
2017 guidelines,[21] the recommended age at 
which to start screening for depression in 
addition to cognitive impairment and demen-
tia in patients with diabetes, with a level B 
evidence, is 65 years. Our study suggests that 
the younger population could require screen-
ing, and this requires further research.
Table 1. Conversion table for HbA1c 
from mmol/mol to %
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Fig. 1. Scatter diagram illustrating the linear relationship between HbA1c and PHQ-9 scores. (HbA1c = 
glycated haemoglobin; PHQ-9 = Patient Health Questionnaire-9.)
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The prevalence of MDD in the general population of SA is 9.7%.[4] 
This is far lower than the 46.6% prevalence of MDD among our study 
participants. If the cut-off for the diagnosis of MDD of a PHQ-9 score 
≥9 had been used, as in the study by Bhana et al.,[19] the prevalence 
would have been 51.1%. This difference of 4.6% requires further 
research to ascertain its clinical significance.
A significantly positive linear relationship was shown between 
the PHQ-9 score and HbA1c (p=0.018253). HbA1c is a surrogate 
marker for glycaemic control. This association provides evidence 
that poor glycaemic control is related to higher PHQ-9 scores, and 
therefore more severe MDD. As this was a cross-sectional study, 
causal relationships could not be established; however, the finding 
remains significant, and, although further studies are required, 
assists in providing evidence in favour of screening for and treating 
MDD in patients with DM. Poor glycaemic control in patients 
with DM and MDD has been described, and depression has been 
shown to worsen the course of chronic conditions.[22,23] To suggest a 
possible solution, a biopsychosocial approach must be utilised. The 
hypothalamic-pituitary axis plays a large role in the pathophysiology 
of depressive disorders, with elevated levels of corticotropin-releasing 
factor found in the cerebrospinal fluid of patients with depression 
and anxiety. [24] Together with increased levels of noradrenaline, 
this results in elevated cortisol.[25] Cortisol is diabetogenic, and an 
elevated cortisol level will result in elevated serum glucose, in turn 
resulting in poorer glycaemic control.[26] The reward pathway in the 
brain may also play a role. Increased consumption of certain food 
types, notably carbohydrates, which are associated with the release 
of dopamine, and chocolate, which contains andamines that promote 
elevated mood, is common in patients with depression.[27] This self-
perpetuating cycle results in poorer glycaemic control, as many of 
these foods result in acute elevation of serum glucose. Psychological 
conditions influence the use of diabetes medication and increase the 
prevalence of poor treatment adherence.[28] This potential influence 
may be attributed to factors such as altered help-seeking behaviour 
due to avolition and feelings of worthlessness. The prevalence of 
MDD has been found to be higher in rural areas compared with 
urban areas.[29] Patients in rural areas may have difficulty in collecting 
their diabetes medication and following up at their local clinics, 
possibly accounting for the above association. Although our study 
took place in a regional hospital in a periurban setting, the diabetes 
clinic drains patients from the second most populous health district 
in KZN, the uMgungundlovu district, of which rural areas form part.
Potential confounders were analysed in an attempt to negate their 
effect on the study results. There were no differences in PHQ-9 score 
when comparing participants without with participants known to 
have the confounders hypothyroidism (p=0.65), epilepsy (p=0.82) 
or HIV (p=0.54). In addition, no relationship was shown between 
PHQ-9 score and BMI (p=0.69). It would appear that these groups 
of participants were equally affected by symptoms of MDD and that 
these confounders imposed no additional risk.
Study limitations
As this was an observational, cross-sectional study, it had many 
intrinsic limitations. Causal inference was difficult to establish, and 
it will remain a challenge in determining which condition preceded 
the other. A distinction was not made between MDD and other mood 
disorders. The symptoms and signs of MDD may be caused by other 
conditions, such as hypothyroidism (although this was analysed).[30] 
These conditions were excluded clinically by the treating clinicians, 
and exclusion was highly dependent on their clinical expertise. The 
diagnosis of depressive disorder due to another medical condition 
(in this instance DM) could account for the depressive symptoms. It 
is difficult to distinguish between MDD and depressive disorder due 
to another medical condition and, for simplicity, we did not attempt 
to do this. [31] Other potential confounders, notably level of education, 
smoking, substance use and psychosocial support, were not recorded.
Conclusions and recommendations
Early diagnosis of MDD is of paramount importance in patients with 
DM. Cardiovascular risk increases markedly in patients with both 
DM and MDD.[14] It has been concluded that patients with both DM 
and MDD are at an increased risk of complications related to diabetes 
as well as early death, and that optimisation of treatment is required 
for optimal patient outcome.[32-34]
The findings of the present study suggest that MDD does in fact 
constitute a problem among individuals with DM in an African 
setting, with 46.6% of patients diagnosed with MDD. A surrogate for 
the severity of MDD (the PHQ-9 score) has a linear relationship with 
measured HbA1c, a surrogate for the control of diabetes. Although 
more studies are required to validate the findings of this study in 
populations in other settings in Africa, routine screening for MDD 
in patients with diabetes is recommended.
It is hoped that the findings of this study will sensitise clinicians to 
the risk of MDD in patients with DM and the potential effect MDD 
may have on their glycaemic control and overall wellbeing.
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